advertisement
Abstract #46034 Published in IGR 13-2
Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys
Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie MJournal of Glaucoma 2011;
PURPOSE: To determine the proportion of latanoprost low-responders among cynomolgus monkeys, and to evaluate the switching efficacy from latanoprost to tafluprost in latanoprost low-responder monkeys. METHODS: Thirty-nine ocular normotensive monkeys were used in this study. Latanoprost low-responders were detected using a 2-step evaluation procedure. In the first step, the response to single administration of latanoprost was investigated in all monkeys. In the second step, the response to 7-day administration of latanoprost was evaluated in screened monkeys. We defined latanoprost low-responders as any monkey that showed intraocular pressure (IOP) reduction of 1 mm Hg or less during the 7-day treatment. Switching efficacy from latanoprost to tafluprost was then evaluated in a 3-phase switching study. Latanoprost was topically administered for about 1 week in phases 1 and 3, with tafluprost being topically administered for about 1 week in phase 2. RESULTS: Eleven monkeys were "latanoprost low-responders." The maximal IOP reduction exhibited by these low-responders in the second step of the evaluation was 0.5(plus or minus)0.2 mm Hg (mean(plus or minus)SEM) during saline treatment and 0.8(plus or minus)0.2 mm Hg during latanoprost treatment. In the 3-phase switching study, the maximal IOP reductions were: 0.4(plus or minus)0.2 mm Hg in phase 1 (latanoprost), 2.4(plus or minus)0.3 mm Hg in phase 2 (tafluprost), and 0.5(plus or minus)0.2 mm Hg in phase 3 (latanoprost). CONCLUSIONS: Latanoprost low-responders exist among cynomolgus monkeys. Switching from latanoprost to tafluprost reduced IOP, and tafluprost's IOP-lowering effect disappeared after switching back to latanoprost in the latanoprost low-responder monkeys. These results suggested that tafluprost might be effective for latanoprost nonresponder patients.
H. Kurashima.
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
5.2 Primates (Part of: 5 Experimental glaucoma; animal models)
